Quantcast

Industry news that matters to you.  Learn more

Sequenom Collaborates With University Medical Center Hamburg-Eppendorf To Evaluate Clinical Utility Of Liquid Biopsy In Colorectal Cancer

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into a clinical collaboration with University Medical Center Hamburg-Eppendorf (UKE) in Germany. UKE and Sequenom will collaborate to profile circulating cell-free tumor DNA in blood to monitor response to treatment in later stage colorectal cancer patients. This technology has the potential to overcome the challenges and limitations associated with current methods such as imaging, colonoscopy, and invasive biopsies.

Personal Genome Diagnostics’ Circulating Tumor DNA Technology Highlighted In Landmark Study

Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, reported that its proprietary technology was used in a major new study being published recently in the journal Science Translational Medicine. The study, “Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies,” assessed the utility of cell-free circulating tumor DNA (ctDNA) for cancer detection and monitoring across multiple patient populations and applications. The authors conclude that ctDNA is a broadly applicable, sensitive and specific biomarker that can be used for a variety of clinical and research purposes in patients with different types of cancer.

Personal Genome Diagnostics Licenses Technology From Johns Hopkins University For Improved Detection Of Cancer Mutations In Circulating DNA

Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, recently reported it has licensed exclusive rights to a technology known as PARE from Johns Hopkins University that is enabling the company to successfully analyze cell-free tumor DNA circulating in patients’ blood. PGDx is now using PARE, other proprietary technologies such as Digital Karyotyping (DK), and the expertise and know-how of its scientists to routinely conduct genomic testing using samples from blood and other bodily fluids, thereby avoiding the need for tumor biopsies.

LEUKOCARE Licenses Biomarker Cell Free DNA to Trillium Diagnostics

LEUKOCARE AG, a German biotech company, and Trillium Diagnostics, LLC, an US-based diagnostic company, announced recently that both partners have formed a strategic alliance regarding the development and marketing of LEUKOCARE’s patented method for the detection of inflammatory activity using the novel biomarker circulating cell free DNA (cf-DNA). Trilium will use the technology to develop a commercial assay for the diagnosis of sepsis.